ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Xcelerate Inc (QB)

Xcelerate Inc (QB) (XCRT)

0.02185
-0.00005
(-0.23%)
Closed February 08 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.02185
Bid
0.0178
Ask
0.0219
Volume
114,643
0.018 Day's Range 0.02185
0.0071 52 Week Range 0.052
Market Cap
Previous Close
0.0219
Open
0.018
Last Trade
5000
@
0.02185
Last Trade Time
Financial Volume
$ 2,419
VWAP
0.0211
Average Volume (3m)
134,405
Shares Outstanding
418,446,072
Dividend Yield
-
PE Ratio
-3.03
Earnings Per Share (EPS)
-0.01
Revenue
1.12M
Net Profit
-2.75M

About Xcelerate Inc (QB)

Xcelerate has assembled an internationally recognized team of translational clinicians, engineers and business leaders to identify, acquire, and develop engineering advancements, intellectual property and operating business in, or with applications in medical technology and clinical care. Xcelerate ... Xcelerate has assembled an internationally recognized team of translational clinicians, engineers and business leaders to identify, acquire, and develop engineering advancements, intellectual property and operating business in, or with applications in medical technology and clinical care. Xcelerate acquires innovation at the engineering / patent level, marries it with appropriate early-stage operational med tech companies and applies it in a controlled clinical care setting which fosters engineering/clinical/business advancements under one umbrella. Show more

Sector
Health Services
Industry
Health Services
Headquarters
Coral Springs, USA
Founded
-
Xcelerate Inc (QB) is listed in the Health Services sector of the OTCMarkets with ticker XCRT. The last closing price for Xcelerate (QB) was $0.02. Over the last year, Xcelerate (QB) shares have traded in a share price range of $ 0.0071 to $ 0.052.

Xcelerate (QB) currently has 418,446,072 shares outstanding. The market capitalization of Xcelerate (QB) is $9.16 million. Xcelerate (QB) has a price to earnings ratio (PE ratio) of -3.03.

XCRT Latest News

Michael O'Shea CEO, Releases Shareholder Update

                                ...

Fran White to Join the Advisory Board of Xcelerate, Inc.

Fran White to Join the Advisory Board of Xcelerate, Inc. Mauldin, SC -- February 15, 2022 -- InvestorsHub NewsWire -- Xcelerate, Inc. (OTC pink sheets: "XCRT”) today...

Xcelerate Files Supplemental Information For Removal of Shell Status

  Xcelerate, Inc. Files to Remove Shell Designation Mauldin, SC -- January 25, 2022 -- InvestorsHub NewsWire -- Xcelerate, Inc. (OTC pink sheets: XCRT) today...

Xcelerate, Inc. Issues Shareholder Update

Xcelerate, Inc. Issues Shareholder Update   Mauldin, SC -- January 12, 2022 -- InvestorsHub NewsWire -- Xcelerate, Inc. (OTC pink sheets: "XCRT) Mike O’Shea...

Xcelerate Acquires Controlling Interest in AfiyaSasa Africa

 Xcelerate Acquires Controlling Interest in AfiyaSasa Africa Mauldin, SC -- January 3, 2022 -- InvestorsHub NewsWire -- Xcelerate, Inc. (OTC pink sheets: "XCRT") today announced it has signed a...

Xcelerate, Inc. Signs Definitive Memorandum of Understanding with HS Pharmaceuticals, LLC

Xcelerate, Inc. Signs Definitive Memorandum of Understanding with HS Pharmaceuticals, LLC   Mauldin, SC -- August 26, 2021 -- InvestorsHub NewsWire -- Xcelerate, Inc...

Xcelerate Completes Audit of Consolidated Annual Financial Statements

Xcelerate Completes Audit of Consolidated Annual Financial Statements   MAULDIN, S.C. -- July 29, 2021 -- InvestorsHub NewsWire -- Xcelerate, Inc. (OTC Pink Sheets: "XCRT"...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0068545.66666666670.0150.027650.0151580340.02501359CS
4-5.0E-5-0.2283105022830.02190.027650.0121723770.01804672CS
120.01325154.0697674420.00860.030.00861344050.01989585CS
26-0.00025-1.131221719460.02210.03050.00711890240.0195051CS
52-0.02515-53.51063829790.0470.0520.00711849560.02370805CS
156-0.03615-62.32758620690.0580.13560.00711790150.04340897CS
2600.020351356.666666670.00150.1740.000896068610.03801709CS

XCRT - Frequently Asked Questions (FAQ)

What is the current Xcelerate (QB) share price?
The current share price of Xcelerate (QB) is $ 0.02185
How many Xcelerate (QB) shares are in issue?
Xcelerate (QB) has 418,446,072 shares in issue
What is the market cap of Xcelerate (QB)?
The market capitalisation of Xcelerate (QB) is USD 9.16M
What is the 1 year trading range for Xcelerate (QB) share price?
Xcelerate (QB) has traded in the range of $ 0.0071 to $ 0.052 during the past year
What is the PE ratio of Xcelerate (QB)?
The price to earnings ratio of Xcelerate (QB) is -3.03
What is the cash to sales ratio of Xcelerate (QB)?
The cash to sales ratio of Xcelerate (QB) is 7.41
What is the reporting currency for Xcelerate (QB)?
Xcelerate (QB) reports financial results in USD
What is the latest annual turnover for Xcelerate (QB)?
The latest annual turnover of Xcelerate (QB) is USD 1.12M
What is the latest annual profit for Xcelerate (QB)?
The latest annual profit of Xcelerate (QB) is USD -2.75M
What is the registered address of Xcelerate (QB)?
The registered address for Xcelerate (QB) is 1700 UNIVERSITY DRIVE, SUITE 200, CORAL SPRINGS, 33071
What is the Xcelerate (QB) website address?
The website address for Xcelerate (QB) is www.uniondentalcorp.com
Which industry sector does Xcelerate (QB) operate in?
Xcelerate (QB) operates in the HEALTH SERVICES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SHWZMedicine Man Technologies Inc (CE)
$ 0.0011
(109,900.00%)
530
ZHCLFZenith Capital Corporation (CE)
$ 0.10
(99,900.00%)
6k
GNCAQGenocea Biosciences Inc (CE)
$ 0.0005
(49,900.00%)
2k
CCTLCoin Citadel (PK)
$ 0.0002
(19,900.00%)
509.6k
TPTWTPT Global Tech Inc (CE)
$ 0.0002
(19,900.00%)
25.08M
BRGOBergio International Inc (PK)
$ 0.000001
(-99.00%)
502k
POLCQPolished Inc (CE)
$ 0.000001
(-99.00%)
130
PUGEPuget Technologies Inc (CE)
$ 0.000001
(-99.00%)
169k
COSGCosmos Group Holdings Inc (PK)
$ 0.000001
(-99.00%)
10M
RNWFRenewal Fuels Inc (CE)
$ 0.000001
(-99.00%)
133
IMTLImage Protect Inc (PK)
$ 0.0001
(-33.33%)
289.87M
ABQQAB International Group Corporation (PK)
$ 0.0003
(-25.00%)
286.78M
PDGOParadigm Oil and Gas Inc (PK)
$ 0.0001
(0.00%)
225.08M
BOMObowmo Inc (PK)
$ 0.0005
(66.67%)
211.25M
RONNRonn Motor Group Inc (PK)
$ 0.0003
(0.00%)
187.29M

XCRT Discussion

View Posts
laraz5 laraz5 2 days ago
4 straight days down after the shoddy paint job Friday?

Remember how gleefull 3rd rate hack promoters were Friday after close trying to paint an idea that something was happening?

Or someone knew something?

Or what it could lead too?

Currently it's led to 4 straight days of PPS decline and probably a 5th day tomorrow?

Hopeful for more paint though Xcelerate Inc is a terrific Friday performer?

IMO

👍️ 1 🚽 1 🥇 1 🧻 2
laraz5 laraz5 3 days ago
Shareholders deserve a full time CEO? Not a part time accountant?

A full time XCRT might have this POS at .07 right now instead taking it from .13 to .02?

A fake .02?

Fridays paint already drying up?

Does Mike even know he's CEO?

Has he ever been to Tanzania?

Did he intentionally skip out on the Microcap conference?

Shoddy at best?

I'd say walk away Mike but that might of been what you had planned all along?

IMO
🌈 1 🏆️ 1 👍️ 1 🧻 1
wxdog wxdog 3 days ago
S/S update this morning. As has been the case for the past almost year and a half now….. UNCHANGED!!!

https://www.otcmarkets.com/stock/XCRT/security
👍️ 2 👎🏿 1 💪 1 💯 2 🧻 1
mike papa mike papa 3 days ago
But,look at how well he did at
the B.F.Borgers incident ?
👍️0
laraz5 laraz5 3 days ago
Part time CEO? Part time forensic accountant or full time Forensic accountant paying no mind as CEO of xcelerate?

How does the board of directors put up with a person moonlighting as a CEO of Xcelerate while doing forensic accounti g for insurance companies out of the same office as Xcelerate?

Why is this acceptable?

Does anyone realize the level of time it takes running investigations into major insurance companies and fraud?

How is a CEO concentrating on his business if all his time is allocated for his other business?

Shareholders deserve better than this? Shareholders do not have stake in forensic accounting company?

They have stake in Xcelerate?

If Mike is still running this forensic accounting out of Xcelerate's office and spend all his time on it the BOD mist act immedialty?

Shareholder value? Does anyone on this board actually care?

IMO
🏆️ 1 👍️ 1
mrwilson31 mrwilson31 3 days ago
Your posts are getting worse by the day. 

Your fantasies of people putting lotion on themselves. 


Talk about low life 3rd party bashers.

That was a new low even for you.

Joe P and LiarZ could be cousins or family Perhaps? 

Things are starting to add up.


👅 1 👍️ 1 👎🏿 1 💯 1
mike papa mike papa 3 days ago
A outstanding job on the forensic part !
👍️0
wxdog wxdog 4 days ago
https://xcelerate.global/bio/

Psychological disorder much?

XCELERATE DIRECTORS
Michael O'Shea, CEO and Director
Mike O’Shea is a forensic accountant and a licensed private investigator. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret Service and ATF. He has been admitted, on numerous occasions, as an expert witness in forensic accounting in both Federal and State court as well as foreign jurisdictions. He has on several occasions, been appointed as a Receiver by the State Court in South Carolina.

Since 1999, Mike has been the Director of Forensic Research Group, Inc. and has been responsible for implementing and supervising its forensic accounting, financial investigation, and corporate due diligence programs. From 1985-1998 Mike served as Director of Investigations for Investigative Research Group, Inc., a firm that specialized in corporate due diligence, asset searches, bankruptcy review, and loan recovery. The Company had Bank of New York, Chemical Bank, Summit Bancorp, and the New Jersey Economic Authority among its long list of noteworthy clients.

Jason Householder, Director
Jason Householder, Co-Founder and CEO of Charlotte based LenDRgroup Consulting, has more than a decade of experience in the healthcare banking field and specializes in assisting medical, dental, and veterinary practices to devise strategies that run their businesses effectively and achieve peak performance. LenDRgroup has financed over $300mil in practice loans to dentists, physicians, and veterinarians.

Jason has experience helping private practice owners, DSO, MSO, corporations, group practices, and hospital systems improve cash flow and profit margins, pursue expansion, acquire real estate, and devise exit strategies. He ranked as the #1 sales producer seven times when working for Bank of America Practice Solutions, Affinity Bank, and NuGrowrh Solutions

Steve Gravely, Director
Steve Gravely, President of the Consulting Group of Jocassee, Inc, has been responsible for the start-up of 25 manufacturing plants around the world and over 300 new product introductions for large corporations such as Michelin, AT&T, NCR, Fluor/Maruti (India), and General Motors. As the Director of Operations for AT&T’s Global Information Solutions (NCR) for both North American and South America, he was responsible for the operation of manufacturing facilities in Brazil, California, and South Carolina.

Formerly, Steve led a high-level corporate acquisition team in the takeover of the third largest computer operation in Brazil. He also owns the computer industry record for computer R&D Development by designing, testing, and delivering a new PC in just 8 weeks while managing a Business Unit for AT&T. Steve is a graduate of Clemson University with a BS in Industrial Engineering.

XCELERATE ADVISORY BOARD
Dr. Dilan B. Ellegala, MD, FAANS
Dr. Ellegala has been at the forefront of clinical care and medical technology development for two decades. An honors graduate of the University of Washington School of Medicine, he served academic leadership roles as Director of Neurotrauma and Cerebrovascular Neurosurgery at major universities, a founding Dean for Global Health, and has had collaborations with the Wellman Center for Photomedicine at MIT/Harvard, Clemson Bioengineering, and private industry. He has authored over 50 peer reviewed research publications and holds multiple patent claims in ultrasound technology. Dr. Ellegala has successfully commercialized medical technology and applied it to advance clinical care. He has founded several successful medical companies including Sonospine LLC, a pioneer in ultrasonic spine surgery, and a virtual health company recently acquired by AdviNOW, LLC which applies artificial intelligence to healthcare.

Dr. Ellegala has received numerous academic and clinical honors and has been consistently recognized for his excellence in patient care. In addition to his pioneering work in the US, he is a testament to the transformational power of teaching and the ever-present potential for change in the world, as demonstrated through his training of health care workers in remote Tanzania to perform brain and spine surgery. His groundbreaking work in global medical education is documented in the book, “A Surgeon in the Village: An American Doctor Teaches Brain Surgery in Africa”, which was written by Pulitzer-nominated journalist Tony Bartleme. NBC’s Tom Brokaw described the work as “A lyrical, inspirational and altogether rewarding account of first- and third-world surgeons working together to perform neurosurgery miracles in the heart of Africa.”

Dr. Barry Marshall, AC. FRACP, FAA,FRS,MBBS-UWA
Professor Barry Marshall is a Nobel Prize Laureate, Professor of Clinical Microbiology at The University of Western Australia. Professor Marshall (1974 UWA graduate) was awarded the 2005 Nobel Prize for Physiology or Medicine for their discovery of the bacterium Helicobacter pylori (H. pylori) and its role in gastritis and peptic ulcer disease. This discovery has benefited millions of people, maybe saving a million lives over the last 10-20 years.
Professor Marshall returned to Perth and UWA in 1996 after a tenure at the University of Virginia. Today, Professor Marshall is the Director of The Marshall Centre for Infectious Diseases Research and Training, which was founded in his honor. In addition to H. pylori research, the Marshall Centre is at the forefront of infectious disease identification and surveillance, diagnostics and drug design, and transformative discovery.
Professor Marshall has several projects including studying the relationship H. pylori has with the immune system. Recent research has found children with H. pylori are 45 per cent less likely to develop asthma. With this as a basis, Professor Marshall and his team are developing a medication that uses the bacteria to rebalance an overactive immune system and prevent asthma and food allergies.
The Helicobacter pylori Research Group is taking up the challenge to develop new diagnostics and treatments to target H. pylori across the globe. The research team is focused on the prevention, diagnosis and treatment of H. pylori using clinical microbiology, molecular biology, immunology, genomics and systems biology.

Cathy Scangarella
Cathy Scangarella is the Chief Business Development Officer and sector lead for Life Sciences at Choose New Jersey, New Jersey’s leading nonprofit economic development organization. Cathy leads the business development team and oversees the organization’s national and international lead generation, prospect management and business development strategy for all key industries. She also oversees the Choose New Jersey India and Europe offices and has enhanced New Jersey’s relationships with key multipliers and trade associations around the globe.

During her tenure at Choose New Jersey, Cathy developed a new tactical business development approach for business attraction efforts to concentrate efforts in key domestic and international markets. She had a leading role in the strategic planning of Choose New Jersey’s business attraction missions to Israel, Germany, Ireland, and India. While abroad, she helped established international university collaborations and industry partnerships for many of New Jersey’s research universities including Rutgers University, Princeton University, New Jersey City University and Rowan University. Notable clients include Ascelia Pharma, BAP Pharma, CSL Plasma, Fordoz Pharmaceuticals, Minerva Biolabs and Biofarma US.

Cathy is a veteran of New Jersey State government, having served six administrations. With over 25 years of experience in marketing, outreach, and business development, she has served as Deputy Chief of Staff to Lt. Governor Guadagno, Director of State Marketing at the New Jersey Business Action Center, Director of Outreach Programs for Business Retention & Attraction at the New Jersey Economic Development Authority, and Vice President of Marketing & Communications for the New Jersey Commerce Commission. Cathy is a member of the Research With New Jersey Advisory Board, the Innovation New Jersey Coalition, and an E&Y Entrepreneur of the Year Judge 2019-2021. She was named among the ROI-NJ Influencers: Women in Business – Economic Development in 2021.

Cathy holds a Bachelor of Science degree in Business Administration with a concentration in Marketing from Ramapo College of New Jersey. Cathy brings a valued new skill set to our Advisory Board. Cathy’s’ experience business development, along with her years of relationships with research institutions, should prove invaluable to Xcelerate as we begin to advance the development of the portfolio of patents recently acquired from HS Pharmaceuticals as well as our continued development of patentable med-tech.

XCELERATE SCIENCE OFFICER
Dr. Anja Glisovic, Chief Science Officer
Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany’s Georg-August Universitat in 2007. She went on to become the head of the R&D Laboratory, Chief Science Officer, and R&D Project Leader for the Fraunhoffer Institute, the world’s leading applied research organization.

Dr. Glisovic will be bringing her vast experience in scientific research and development, as well as project leadership at the highest levels, to the Xcelerate Team. She holds numerous patents in the fields of medical devices, chemical engineering, and small arms and munitions. Her primary initial responsibility with the Xcelerate will be identifying and developing business combinations and high growth opportunities in the medical arena.

XCELERATE COUNSEL
Andrew I. Telsey, Securities Attorney
Andrew Telsey is an “AV” rated attorney (the highest rating) and has been practicing law in the State of Colorado since 1980. Since 1984, Mr. Telsey has been President and sole shareholder of Andrew I. Telsey, P.C., Centennial, Colorado, a law firm emphasizing securities law, business transactions, mergers and acquisitions, cannabis transactions and general corporate matters for developmental stage and emerging growth companies both nationally and internationally.

Since July 2017, Mr. Telsey has been Of Counsel to the Hoban Law Group, the largest cannabis law firm in the US, where he has been the lead attorney in the securities department.

Mr. Telsey received a Juris Doctor degree from Syracuse University College of Law in 1979 and a Bachelor of Arts degree Magna Cum Laude, from Ithaca College in 1975. He was also named as one of Denver’s Top Lawyers by the Denver Post from 2015-2018.
👎🏿 1 🚽 1
laraz5 laraz5 4 days ago
XCRT appears to be a ship without a Captain?

PPS wise like the Titanic but nothing has happened with XCRT once Joe Pignatiello got sick?

You remember the sales and marketing director who was tied to previously shell who blindsided 3rd party promoters with his status with Xcelerate?

I'm not sure what happened but when he got sick before he passed away, XCRT went silent?

Why? Who was controlling the flow of information?

Is mike still at the helmet?
Was he ever?
Patsy?
Health deteriorating also?

I knew there was a problem when Mike went radio dark after the microcap conference?

This is getting worse by the day?

IMO

🏆️ 1 👍️ 1
laraz5 laraz5 4 days ago
Are you saying Caremedx is disgusting or the people who use it?

This is an outlandish claim?

Unprecedented?

Disgusting could be considered as taking a publicly traded company from .13 to .013 but if in fact people who used the product describe it as Disgusting is a much bigger issue?

3rd party hack promoters might want to go on damage control after these new claims?

IMO
👍️0
mrwilson31 mrwilson31 4 days ago
Pretty disgusting that you would say  people were rubbing it all over their family members.

Common decency is all we ask for.

Should be ashamed of yourself.

Then again you never are.
👅 1 👎🏿 1
wxdog wxdog 4 days ago
Generating revenues on just one of the multi platforms being instituted? Extremely stable share structure which is unheard of in the OTC realm. Low Float. Many shares in tight hands. Next round of updates XCRT will pop nicely. Board is quiet awaiting updates. Hang in there negative Nancy’s 😆🤣😆

XCRT SECURITY DETAILS
Share Structure

Market Cap Market Cap
9,731,592 02/03/2025

Authorized Shares
1,000,000,000 01/30/2025

Outstanding Shares
434,446,072 01/30/2025

Restricted
288,289,635 01/30/2025

Unrestricted
146,156,437 01/30/2025

Held at DTC
123,964,786 01/30/2025

Float
113,254,437 12/31/2023

Par Value
0.0001
👍️0
laraz5 laraz5 4 days ago
I enjoyed when all these slimy 3rd party con promoters started claiming they and their family were all rubbing caremedx all over each other and it miraculously cured them?

Can we get back to that moment?

It was glorious?

IMO
👍️0
wxdog wxdog 4 days ago
More great reviews-

https://earthsciencebeauty.com/
👍️0
wxdog wxdog 4 days ago
Great reviews-
https://ceramedx.com/products/restoring-body-lotion
👍️0
wxdog wxdog 4 days ago
Not a single share added to share count in almost a year and a half!!!! Hard to find…even in OTCQB land.

https://www.otcmarkets.com/stock/XCRT/security
💯 1 😎 1 🥳 1
wxdog wxdog 4 days ago
https://www.otcmarkets.com/filing/html?id=17852428&guid=Qb0-kK5UOIxmh3h

https://www.otcmarkets.com/filing/html?id=17485524&guid=Qb0-kK5UOIxmh3h
👍️0
laraz5 laraz5 4 days ago
Great job Mike following up on the empty Friday paint job?

Could of used that moment for an update or to prove you are still even alive?

Unlike the Microcap conference debacle?

But in XCRT fashion let it just dwindle back to obscurity?

All while clowns tell everyone else PPS that go from .13 to .013 is not dilution?

Just dumb luck?

Did the bid ever rise after Fridays horrific paint job?

Who knows?

Glad shareholders have ESN revenue to fall back on? Remember that dynamite buy? 350k for immediate revenue in the millions?

Great business investment by ESN?

IMO

🌈 1 ⁉️ 1
wxdog wxdog 6 days ago
What is just absolutely hilarious is the fact that the average share price has been hovering around the .02’s for most of the past year. Which also coincides with Borgers throwing that nasty money wrench into the mix. Go figure. Ineptitude doesn’t really equal substance. At all in this case!

Go XCRT
🌩️ 1 👍️ 2 👎🏿 1
wxdog wxdog 6 days ago
Unchanged for almost 1 and 1/2 years now?

Not my opinion NMO!

https://www.otcmarkets.com/stock/XCRT/security
👍️ 1 🧻 1
wxdog wxdog 6 days ago
https://www.otcmarkets.com/filing/html?id=17852428&guid=aE0-kKk9hQP2h3h

https://www.otcmarkets.com/filing/html?id=17485524&guid=aE0-kKk9hQP2h3h
🚽 1
laraz5 laraz5 6 days ago
Here we go with the "you won't be able to get shares" BS again?

From .13 ro .04 the same people told you not to be left on the sidelines?

The float was drying up?

No dilution?

News and revenues coming?

Strange they all dissapeared when XCRT went into a toxic death spiral and sank 90%?

But all of a sudden they re appear when XCRT does the late Friday paint?

They are back for more selling?

When they are telling to buy you know they are about to dump?


Watch?

IMO
🏆️ 1 👍️ 1
wxdog wxdog 6 days ago
Also, most of the Float is in the hands of folks that are aware of the aforementioned. Won’t be easy to get a large amount of shares under a nickel once Xcelerate starts moving again.

Up 80% on thin air…literally!

Imagine where the share will go on a bullish couple million “shares traded” day. Boomage most likely!
👅 1 👍️ 1 💥 1 💯 2 😎 1 🚽 1 🥳 1
wxdog wxdog 6 days ago
Indeed….

It’s only a matter of time. Patience can be a struggle at times. But I do believe it’ll come to fruition here with Xcelerate here at some point. Waiting game.

If there was a ton of dilution just to keep the lights on (and fluff PR’s) I wouldn’t be here. Which is the case with the vast majority of OTC Tickers. When you read through the Annuals/Semi’s you see where (outside of company expansion issues) everything is self funded? Including extra auditors fees. We know the ESN Group is generating revenue. AfiyaSasa grows some legs XCRT will be off to the races.

Could easily break a dime plus again!
👎🏿 1 💯 2 😎 1 🥳 1 🧻 1
GREGG THE GREEK GREGG THE GREEK 6 days ago
The best is someone didn't fully rise from the dead obviously lol

They claim there's only dilution and selling ...no one is buying..yet now they say phantom sellers ? lolol

I mean it's hard to keep up with BS.


And it's obvious there's no dilution since the updates keep showing us reality.
👍️0
wxdog wxdog 1 week ago
Nothing like an 80% pop in share price on NO news. And, No volume! Much of the Float (awfully small one at that) is in more patient hands now. Imagine what XCRT/share price will do once we get some news on the good side!

No updates in a while, right along with ZERO dilution? Generating income through the ESN Group. Borgers really put a damper on what they had going on last year. Takes time to clear up all the paperwork involved. So, could be they are working on getting things lined up to move forward.

I sure ain’t going anywhere…regardless of the opines of a couple serious Debbie-Downers😂😂😂😂
👍️ 1 💯 1
laraz5 laraz5 1 week ago
No dilution but in the same sentence, phantom sellers drying up?

Total clowns?

These sellers?

Who?

.174 to .013 is dilution?

IMO
🌈 1 🌚 1
GREGG THE GREEK GREGG THE GREEK 1 week ago
Over and over and over again we see there is no dilution here. They update it quire regularly.


So, at some point the sellers dry up and the SP rebounds.

Now we just need some solid updates and we'll be moving north again. jmo


XCRT
👍️ 3 💥 2 💪 1 💯 2
findit findit 1 week ago
Long time no see. What ya think about today's move? +79% to .02756 volume 313k.
👍️ 2
mike papa mike papa 1 week ago
Liquidity & capital resources disheartening !
👍️0
wxdog wxdog 1 week ago
https://www.otcmarkets.com/filing/html?id=17852428&guid=jh0-ke1lnfZnJth
👍️ 1 🔄 1
laraz5 laraz5 1 week ago
Wonder if shareholders had a choice of a .13 PPS and dilution in the last year or a .013 PPS with no dilution in the last year?

Oh the choices?

I hope the next wave of dilution is like the last one, this time drop 100,000,000 millions shares to a 3rd party then trickle sell them over a year period so dimwits can boast about no dilution in over a year while the PPS continues to tank?

IMO

🏆️ 1 👍️ 1
mike papa mike papa 1 week ago
Benevolence is my nature !
😁 1
wxdog wxdog 1 week ago
S/S Update this morning. UNCHANGED! It’s now been ~ a year and half since it’s changed. Revenues going up and dilution? Not going up? Market Cap $6 million. Next update she pops. IMO

https://www.otcmarkets.com/stock/XCRT/security
👍️ 1 💯 1 🧻 1
mahatmapaul mahatmapaul 2 weeks ago
You're being too charitable! $0.174 to $0.0125
🏆️ 1 👍️ 1 🛒 1 🧻 1
mike papa mike papa 2 weeks ago
So $0.174 to $0.0145 is no dilution. > WOW < !
😁 1
laraz5 laraz5 2 weeks ago
Bid is now .012? Does Shoddy O'Shea have a rebuttal?

From .13 to .012 yet these clowns over various social media platforms just keeping deflecting the blame on anyone except the part time CEO who has destroyed shareholder value?

Did Mike drop the ball on Affiyasassa?
Hire a convicted felon to run marketing?
Lie about financials?

I wouldn't worry though some silly 3rd party promoter should come along any moment and tell everyone what another buying opportunity this is and how much money they are making while the PPS flies into a death spiral?

IMO
🏆️ 1 👍️ 1
mrwilson31 mrwilson31 2 weeks ago
Of course you have no rebuttal.
Just shaking that crystal ball negativity. Baking stuff up per usual.
Nothing of substance.
👍️ 2 👎🏿 1 💥 1 🚽 1
laraz5 laraz5 2 weeks ago
Always an excuse for Shoddy O'Shea?

From every level .13 to .013 these horrendous 3rd party con artist, vomit up excuses all over social media for Mr. "WERE DONE"?

Is that how mike could walk away from Xcelerate?

The same way he walks out of depositions saying we're done?

Is bankruptcy "we're done"?

Is no accountability for affiyasassa revenue as promised come to a "we're done"?

Is it a "We're done" after shareholders sitting at a 90% loss on their Investment in XCRT?

As the old saying goes Is Mike just going to S@#% and walk away?


IMO
👍️ 2 😁 1 🥇 1
wxdog wxdog 2 weeks ago
Blah, blah, blah….

Pre Xcelerate??

I know/known a bunch of professionals that do great work in their fields. Most all have had an issue or two. It comes with the territory.

Get a life already!
👍️ 1 💥 2 💯 2 🧻 1
laraz5 laraz5 2 weeks ago
Holy Smokes how did I miss that?

Michael O'Shea a part time CEO failing on his other promises as well as XCRT?

Now this is solid DD, bravo!

Shoddy O'Shea?

IMO
👍️ 1 😁 1 🧨 1
wxdog wxdog 2 weeks ago
S/S Unchanged. No dilution continues!

https://www.otcmarkets.com/stock/XCRT/security
👍️ 1 💪 2 🤑 1
mahatmapaul mahatmapaul 2 weeks ago
Wow the pot calling the proverbial kettle black!

Just as you folks have been saying for several years now that XCRT is the real deal .... you better load up ... better stock up right now 'cause it's gonna be skyrocketing ... and yet the pps slowly slowly drops this whole time

... and yet again Michael O'shea lied for the seventh time when he clearly stated that there would be revenue starting in the fourth quarter of 2024 from Africa operations

before you criticize the little piece of wood in someone else's eye, better get the big piece of wood out of your own.

And please no childish rationalizations such as the accounting issue, as if an administrative hassle would prevent a multi million dollar investment that has been forecast continually for 3 years .... michael O'shea has been lying about Africa ... What else is he lying about?

And of course since you fellows do such good DD you must know that O'shea has been very busy in recent times with his forensic accounting! He hasn't been a full time CEO by any means of XCRT ..... in a recent court case, the court took O'shea to the woodshed calling his forensic accounting shoddy ... he was forced into a deposition to discuss an egregious oversight on his part In his analysis of a major insurance fraud ..... The purpose of the deposition was to find out if O'shea had colluded with the perpetrator of the fraud, since his shoddy work seemed to be protecting one of the parties accused of fraud

Why don't you guys go find this case? .... it's publicly available and you guys do such good dd

what Pompous morons on the OTC!
👍️0
THEDOG 17 THEDOG 17 2 weeks ago
Holy cow you’ve been saying that for over a year! Wrong! Go Xcrt!
👍️0
mrwilson31 mrwilson31 2 weeks ago
We know who the pumping clowns really are. All one has to do is look at posting history. 


👍️0
laraz5 laraz5 2 weeks ago
Next up Sub Penny? Is that in the filings?

From .174 to .013?

Do they address that?

Bozo 3rd party clowns pumping trash and assumptions from .13 to .013 do they account for that?

Imagine pumping this crap at .10 then coming back to bragging about your position?

Or how much money you've made on the toxic death spiral the PPS went?

Great stuff?


IMO

👍️0
wxdog wxdog 2 weeks ago
Damn you’re dense! Read the first entry under “Revenues”. Revenue of $1,122,085 were recorded for Xcelerate as of Dec 31, 2023. It has nothing to do with the “boiler plate” verbiage in the filing. Wow🤠

2024 revenues will no doubt far exceed 2023’s.

Joe P has never been in the loop fool. That was a dig on the stupidity of any ever thinking he was. Geese. Read the filings instead of plastering gibberish all over this thread. PLEASE!!!

Revenues

Total Revenue 1,122

https://www.otcmarkets.com/stock/XCRT/financials
👍️0
laraz5 laraz5 2 weeks ago
" The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements./i]"

Everything these hack promoters regurgitate is an assumption?

From .13 to .013 nothing but assumptions?

When you call them out on their assumptions they copy and paste literally someone telling you it's an assumption?

Do they ever do there own DD?

PS Joe died, which might be why no one has heard anything from Xcelerate or Mike, he's gone darker than the Hawk Tuah girl?

Where in the world is Mikey Oshandiego?

IMO
👍️0
wxdog wxdog 2 weeks ago
Cost of product, delivery, advertising, services, fees, service charges, losses of product, employees…on and on and on, are all why a company also has account fees.

A lot goes into running a company - more so when you have subsidiaries under your umbrella - a little like Xcelerate. IMO
👍️0
wxdog wxdog 2 weeks ago
Hmm, why would “the acquisition of ESN” be in the most recent filing of an Xcelerate 1-SA SEC Filing? Weird IMO

Dammit, maybe I should read more about Xcelerate instead of throwing chit on the wall to see if I get attention….naw, sounds too much like actual work. IMO


Start of page 14:


[The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements. The most significant estimates relate to the calculation of stock-based compensation, accounting for the ASA transaction, accounting for the acquisition of the ESN, income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements./i]
👍️0

Your Recent History

Delayed Upgrade Clock